An update on the Endpoints business model — and how your company can directly support it
Pictured: The print-optimized version of Endpoints’ 2018 New Drug Approvals report. All paid subscribers will receive a direct link to download the PDF + a copy of all our Q1 paywall stories in printable form, too.
I want to give readers an update on the business front at Endpoints News, which is strong.
Two and a half years in — we’re profitable, about 14 people on the team and growing, and 75,000 unique biopharma readers consume our news across all platforms on a weekly basis. Of that, 31,000 are what we consider “basic subscribers” who receive our daily email reports and have opened or clicked on them in the last month, but haven’t upgraded to paid status. And at the top we have 8,300 premium subscribers who either directly support the work or are employed at a company that does.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.